COVID-19 Antibodies Among Healthcare Workers

Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers in a COVID-19 Unit

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04425889

Enrollment

156

Registered

2020-06-11

Start date

2020-05-05

Completion date

2020-06-01

Last updated

2020-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, SARS-CoV 2

Brief summary

Observational, point of prevalence study determining the presence of anti-SARS-CoV-2 antibody

Detailed description

All Healthcare workers (HCW) who had entered contaminated areas at least once and that 14 days or more had passed from their first entrance to contaminated areas were included. They were classified as asymptomatic and pauci-symptomatic. A COVID-19 IgG/IgM rapid test was used for antibody detection, and selected participants were subject to real time polymerase chain reaction (qPCR) for SARS-CoV-2.

Interventions

DIAGNOSTIC_TESTCOVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)

a blood sample is drained for detection of IgG and IgM antibody

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

* All healthcare workers who had entered contaminated areas at least once and that 14 days or more had passed from their first entrance were included

Exclusion criteria

* Healthcare workers who did not have exposure for more or equal 14 days * Healthcare workers who did not wish to participate

Design outcomes

Primary

Measure	Time frame	Description
Presence of antibody	through study completion, an average of 8 weeks	presence of IgG and/or IgM against SARS-CoV-2

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026